The Experts below are selected from a list of 18801 Experts worldwide ranked by ideXlab platform
David B. Stewart - One of the best experts on this subject based on the ideXlab platform.
-
Palliative Therapy for stage IV rectal adenocarcinoma: how frequently is it used?
The Journal of surgical research, 2017Co-Authors: Audrey S. Kulaylat, Emily B. Rivet, Christopher S. Hollenbeak, David B. StewartAbstract:Abstract Background Palliative care is associated with decreased cost and improved quality of life, although its use in stage IV rectal cancer is understudied. Materials and methods Stage IV rectal cancer patients (2004-2011) who did not undergo surgery with curative intent were identified within the National Cancer Database. Patients receiving Palliative Therapy were stratified by the type of intervention, as were patients undergoing chemoTherapy that was not designated as Palliative. Logistic regression was used to identify factors associated with the receipt of Palliative Therapy. Results A total of 11,245 patients were analyzed, of which 2314 (20.6%) received Palliative Therapy. Use of Palliative Therapy as a category of treatments did not change significantly from 2004-2012 (19.4%-23.0%; P = 0.14), but the use of Palliative chemoTherapy nearly doubled (4.7%-8.7%; P 60 y and increasing chronic comorbidities; these subgroups also had lower odds of receiving chemoTherapy that was not designated as Palliative. Differences in gender and race were not associated with variations in the receipt of Palliative Therapy. Conclusions For stage IV rectal cancers managed without curative intent, use of Palliative therapies remains consistently low, with a preference for sicker patients.
Hsing Hseuhping - One of the best experts on this subject based on the ideXlab platform.
-
Palliative Therapy for infants with tetralogy of Fallot by percutaneous balloon pulmonary valvuloplasty
Chinexe Journal of Pediatrics, 2000Co-Authors: Hsing HseuhpingAbstract:Objective To evaluate the efficacy of Palliative Therapy for infants with tetralogy of Fallot by percutaneous balloon dilatation of the right ventricalar outflow tract. Methods In cardiac catheterization laboratory, aortic oxygen saturation and pressure in right ventricle and pulmonary arteries were measured in 16 infants aged 2-12 months with tetralogy of Fallot before and after balloon dilatation of the right ventricular outflow tract. The diameters of pulmonary annuli, first branches of right and left pulmonary arteries, as well as ascending and descending aortae were also measured by cineangiography before and after balloon dilatation. Results (1) The oxygen saturation in aortae increased from 0.74 to 0.82 ( P 0.01) after the balloon dilatation. (2) The pressures in right ventricle and pulmonary arteries didn′t show significant changes ( P 0.05) after the procedure. (3) The diameters of pulmonary annuli, first branches of right and left pulmonary arteries increased significantly ( P 0.0001). The diameters of aortae also increased significantly ( P 0,05) following catheterizations up to one year in 14 of 16 cases. Conclusion The percutaneous balloon dilatation of the stenotic right outflow tract is one of the effective Palliative therapies for infants with tetralogy of Fallot.
Audrey S. Kulaylat - One of the best experts on this subject based on the ideXlab platform.
-
Palliative Therapy for stage IV rectal adenocarcinoma: how frequently is it used?
The Journal of surgical research, 2017Co-Authors: Audrey S. Kulaylat, Emily B. Rivet, Christopher S. Hollenbeak, David B. StewartAbstract:Abstract Background Palliative care is associated with decreased cost and improved quality of life, although its use in stage IV rectal cancer is understudied. Materials and methods Stage IV rectal cancer patients (2004-2011) who did not undergo surgery with curative intent were identified within the National Cancer Database. Patients receiving Palliative Therapy were stratified by the type of intervention, as were patients undergoing chemoTherapy that was not designated as Palliative. Logistic regression was used to identify factors associated with the receipt of Palliative Therapy. Results A total of 11,245 patients were analyzed, of which 2314 (20.6%) received Palliative Therapy. Use of Palliative Therapy as a category of treatments did not change significantly from 2004-2012 (19.4%-23.0%; P = 0.14), but the use of Palliative chemoTherapy nearly doubled (4.7%-8.7%; P 60 y and increasing chronic comorbidities; these subgroups also had lower odds of receiving chemoTherapy that was not designated as Palliative. Differences in gender and race were not associated with variations in the receipt of Palliative Therapy. Conclusions For stage IV rectal cancers managed without curative intent, use of Palliative therapies remains consistently low, with a preference for sicker patients.
-
Utilization and trends in Palliative Therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study
Journal of gastrointestinal oncology, 2017Co-Authors: Audrey S. Kulaylat, Christopher S. Hollenbeak, Katelin A. Mirkin, Joyce WongAbstract:Background: Pancreatic adenocarcinoma is an aggressive malignancy, with most patients diagnosed with advanced or metastatic disease. Palliative therapies comprise an important, but underutilized, aspect of care. This aim of this study was to characterize the trends, factors, and outcomes associated with utilization of Palliative therapies. Methods: Patients with stage IV pancreatic adenocarcinoma from the 2003–2011 U.S. National Cancer Database were identified and stratified by receipt of Palliative Therapy. Linear regression, multivariable logistic regression, and survival analyses using multivariate proportional hazards models were performed. Results: Sixty-eight thousand and seventy-five patients with stage IV disease were identified, of which only 11,449 (16.8%) underwent designated Palliative Therapy. The majority received systemic chemoTherapy (37.2%), followed by surgery (19.0%), pain management alone (15.3%), radiation (8.1%), referral alone (11.7%), or a combination thereof (8.7%). Utilization of Palliative therapies increased from 12.9% in 2003 to 19.2% in 2011 (P Conclusions: Despite the continued dismal prognosis of pancreatic cancer, palliation of symptoms remains underutilized in this country, particularly in non-Caucasian, older patients. Increased awareness of Palliative options may help increase its utilization.
Wu B - One of the best experts on this subject based on the ideXlab platform.
-
Strontium~(89) in Palliative Therapy for late-stage prostate cancer with bone metastases
Hainan Medical Journal, 2010Co-Authors: Wu BAbstract:Objective To study the clinical efficacy of strontium89 (Sr89) in Palliative Therapy for late-stage prostate cancer with bone metastases.Methods 30 patients with painful bone metastases of prostate cancer received bilateral orchectomy and intravenous injection of Sr89 at the dose of 1.48-22.22MBq (40-60μCi) /kg.Then we analysed the clinical effect by follow-up.Results After the treatment of Sr89,pain alleviated in 90.0%,with an absolute palliation rate of 36.7%.Pain palliation started at 3-18 days and lasted for 3-11 months.The WBC count decreased 20.8% of the patients averagely,with PLT count decreased 29.1%.They can return to mormal after 3 months.6 months later,21 were followed-up by single-Photon Emission Computed Tomography,and found that 9(42.9%) of them exhibited an obvious decrease in the number of metastases,8 (38.1% ) stabilized and only 4 (19.0% ) deteriorated.Conclusion Sr89,capable of inhibiting bone metastasis,relieving pain and improving the quality of life of patients with few adverse effects,can be used as a desirable Palliative Therapy for late-stage prostate cancer with bone metastases.
E. Felekouras - One of the best experts on this subject based on the ideXlab platform.
-
Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemoTherapy: A retrospective analysis
EJSO - European Journal of Surgical Oncology, 2011Co-Authors: S. Sougioultzis, J. Syrios, I.d. Xynos, N. Bovaretos, C. Kosmas, J. Sarantonis, A. Dokou, D. Tzivras, G. Zografos, E. FelekourasAbstract:Most patients with gastric cancer present with locally advanced or metastatic disease and usually receive Palliative Therapy. We sought to identify factors influencing overall survival in patients with stage IV gastric cancer receiving Palliative chemoTherapy.
